Interim report
Page 1
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Quarterly Statement Q3 2025 December 1, 2024 to August 31, 2025 Contents 2 Key Figures 3 Revenue, Adjusted EBITDA and Free Cash Flow 5 Forecast 2025 6 Financial Information 11 Additional Information
Page 2
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Key Figures 2 Change in % Change in % In EUR m Q3 2025 Q3 2024 Actual Organic 9M 2025 9M 2024 Actual Organic Results of operations Revenues 560.7 498.5 12.5 – 1,681.4 1,467.0 14.6 – Adjusted EBITDA 103.4 104.4 –1.0 – 313.9 292.7 7.2 – Adjusted EBITDA margin in % 18.4 21.0 –260bps – 18.7 20.0 –130bps – Revenues (organic)1) 576.2 583.4 – –1.2 1,705.3 1,737.2 – –1.8 Adjusted EBITDA (organic)1) 108.1 119.4 – –9.4 320.7 346.6 – –7.5 Adjusted EBITDA margin in % (organic)1) 18.8 20.5 – –170bps 18.8 19.9 – –110bps Adjusted net income2) 24.4 40.6 –39.8 – 72.3 107.1 –32.5 – Earnings per share in euros3) –0.37 0.79 >-100.0 – –0.40 2.10 >-100.0 – Adjusted EPS in euros4) 0.69 1.16 –40.5 – 2.05 3.06 –33.0 – Adjusted EPS in euros (currency-adjusted)4) 0.77 1.20 – –35.8 2.16 3.20 – –32.5 Financial position Cash flow from operating activities 85.5 71.3 20.0 – 119.8 106.5 12.5 – Cash-effective capital expenditure –67.8 –82.1 17.4 – –250.4 –279.9 10.5 – Cash flow from investing activities –65.0 –76.1 14.5 – –594.4 –268.7 >-100.0 – Free cash flow before M&A activities 20.5 –4.8 >100.0 – –118.8 –152.8 22.3 – In EUR m Aug. 31, 2025 Nov. 30, 2024 Change in % Actual Organic Net assets position Total assets and total liabilities 4,686.8 3,809.2 23.0 – Equity 1,427.8 1,539.1 –7.2 – Equity ratio in % 30.5 40.4 –990bps – Net working capital (reporting date) 336.5 232.7 44.6 – Net financial debt 2,015.9 1,100.3 83.2 – Adjusted EBITDA leverage6) 4.15 2.43 – – Employees Employees (reporting date) 13,535 12,142 11.5 – 1) Organic revenue and organic adjusted EBITDA include the revenue and adjusted EBITDA of Bormioli Pharma in both 2024 and 2025, which we acquired on December 10, 2024 and fully consolidate from the beginning of the financial year 2025, translated at the budgeted exchange rates for the financial year 2025. 2) Adjusted net income: Net income before depreciation/amortization/impairment losses of fair value adjustments less capitalized cost components, and restructuring expenses, as well as before the balance of exceptional income and expenses and the related tax effects. 3) Earnings per share in euros: Earnings per share attributable to shareholders of Gerresheimer AG, based on 34.540m shares. 4) Adjusted EPS in euros: Adjusted earnings per share attributable to shareholders of Gerresheimer AG, based on 34.540m shares. 5) Based on adjusted EPS in euros excluding the earnings contributions of Bormioli Pharma for Q3 2024 and 9M 2024, translated at the budgeted exchange rates for the financial year 2025, based on 34.540m shares. 6) Adjusted EBITDA leverage: The relation of net financial debt to adjusted EBITDA of the last twelve months according to the credit agreement currently in place. Key Figures
Page 3
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Revenues, Adjusted EBITDA and Free Cash Flow 3 Plastics & Devices Change in % In EUR m Q3 2025 Q3 2024 Actual Organic Revenues1) 324.0 278.6 16.3 2.5 Adjusted EBITDA 71.5 70.4 1.7 –7.0 Adjusted EBITDA margin in % 22.1 25.3 –320bps –230bps Change in % In EUR m 9M 2025 9M 2024 Actual Organic Revenues1) 972.6 820.1 18.6 2.6 Adjusted EBITDA 222.6 208.5 6.8 –6.6 Adjusted EBITDA margin in % 22.9 25.4 –250bps –230bps 1) The revenues of the divisions include intercompany revenues. Revenues in the Plastics & Devices Division amounted to EUR 972.6m in the first nine months of the financial year 2025, compared to EUR 820.1m in the same period of the prior year , which reflects an increase of 18.6%. The increase is primarily due to the first-time inclusion of the revenue contribution from Bormioli Pharma. Taking into account the revenue of Bormioli Pharma in the period from December 2023 to August 2024 and adjusted for foreign exchange rate effects, revenues increased by 2.6% compared to the prior -year period. The exchange rate effects resulted mainly from the change in the US dollar against the euro. The high demand for drug delivery systems compensated for the temporary market weakness in plastic containment solutions for oral liquids. Adjusted EBITDA was up by 6.8% and organically down by 6.6% compared to the same period in the prior year. The organic adjusted EBITDA margin of 22.9% reflects lower capacity utiliza- tion at Oral Liquids due to lower market demand as well as start-up costs for the ramp -up of new production lines and lower capacity utilization during the start-up phase for drug de- livery systems. Primary Packaging Glass Change in % In EUR m Q3 2025 Q3 2024 Actual Organic Revenues1) 239.6 221.5 8.2 –5.5 Adjusted EBITDA 42.0 45.4 –7.6 –13.8 Adjusted EBITDA margin in % 17.5 20.5 –300bps –170bps Change in % In EUR m 9M 2025 9M 2024 Actual Organic Revenues1) 714.4 648.0 10.3 –6.9 Adjusted EBITDA 127.2 119.7 6.2 –7.2 Adjusted EBITDA margin in % 17.8 18.5 –70bps – 1) The revenues of the divisions include intercompany revenues. In the Primary Packaging Glass Division, revenues of EUR 714.4m were generated in the first nine months of the financial year , after EUR 648.0m in the prior-year period. This increase of 10.3% is primarily due to the first-time inclusion of the revenue contri- bution from Bormioli Pharma. Taking into account the revenue of Bormioli Pharma in the period from December 2023 to August 2024 and adjusted for foreign exchange rate effects, revenues in the first nine months of the financial year 2025 were 6.9% lower than in the same period of the prior year. The exchange rate effects resulted mainly from the change in the US dollar against the euro. The organic decline in sales was caused, among other things, to continued subdued demand in the cosmetics business and in the oral liquid business in the pharmaceuticals sector. Among others, demand for our Gx ® RTF vials developed positively. Adjusted EBITDA increased by 6.2%, respectively decreased or- ganically by 7.2% compared to the first nine months of the prior year. The decline in adjusted EBITDA is primarily attributable to a decrease in demand in the Moulded Glass Business Unit. The adjusted EBITDA margin decreased by 70 basis points to 17.8%, after 18.5% in the same period of the prior year. The organic ad- justed EBITDA margin remained unchanged at 18.0% (9M 2024: 18.0%). Revenues, Adjusted EBITDA and Free Cash Flow
Page 4
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Revenues, Adjusted EBITDA and Free Cash Flow 4 Advanced Technologies Change in % In EUR m Q3 2025 Q3 2024 Actual Organic Revenues1) 1.1 1.4 –20.4 –20.4 Adjusted EBITDA –4.1 –5.0 17.5 18.7 Adjusted EBITDA margin in % – – – – Change in % In EUR m 9M 2025 9M 2024 Actual Organic Revenues1) 3.9 4.1 –6.5 –6.5 Adjusted EBITDA –12.3 –13.6 9.2 10.7 Adjusted EBITDA margin in % – – – – 1) The revenues of the divisions include intercompany revenues. At EUR 3.9m, revenue in the Advanced Technologies Division in the first nine months of the financial year 2025 was on a par with the same period of the prior year. Adjusted EBITDA im- proved year on year to EUR -12.3m. The division’s development projects, amongst them digital plat- forms for therapy support, wearable medication pumps for small- and large-molecule drugs, and the proprietary auto-injec- tor platform, are continuing as planned. Reconciliation of Adjusted EBITDA Change in % In EUR m Q3 2025 Q3 2024 Actual Organic Plastics & Devices 71.5 70.4 1.7 –7.0 Primary Packaging Glass 42.0 45.4 –7.6 –13.8 Advanced Technologies –4.1 –5.0 17.5 18.7 Corporate functions/ consolidation –6.0 –6.4 6.1 – Adjusted EBITDA 103.4 104.4 –1.0 –9.4 Change in % In EUR m 9M 2025 9M 2024 Actual Organic Plastics & Devices 222.6 208.5 6.8 –6.6 Primary Packaging Glass 127.2 119.7 6.3 –7.2 Advanced Technologies –12.3 –13.6 9.6 10.7 Corporate functions/ consolidation –23.6 –21.9 –7.8 – Adjusted EBITDA 313.9 292.7 7.2 –7.5 Free Cash Flow In EUR m Q3 2025 Q3 2024 Change Cash flow from operating activities 85.5 71.3 14.2 Net capital expenditure before M&A activities –65.0 –76.1 11.1 Free cash flow before M&A activities 20.5 –4.8 25.3 In EUR m 9M 2025 9M 2024 Change Cash flow from operating activities 119.8 106.5 13.3 Net capital expenditure before M&A activities –238.6 –259.3 20.7 Free cash flow before M&A activities –118.8 –152.8 34.0 In the first nine months of the current financial year, cash flow from operating activities amounted to EUR 119.8m, compared to EUR 106.5m in the same period of the prior year. The adjusted EBITDA for the first nine months was higher than in the same period of the prior year. Lower funds locked up in net working capital compared with the same period of the pr ior year had a positive effect on cash flow from operating activities. Interest payments on variable-rate debt, which rose compared with the same period of the prior year, reduced cash flow from operating activities.Taking into account the above-mentioned effects and net capital expenditure, free cash flow before M&A activities amounted to EUR -118.8m as of August 31, 2025, compared to EUR -152.8m in the same period of the prior year. Net capital expenditure in the first nine months of the financial year includes payments from government grants in the amount of EUR 9.3m (9M 2024: EUR 18.4m). Capital expenditure in the Plastics & Devices Division focused on the further expansion of syringe capacities in Germany, Mexico, and the Republic of North Macedonia, as well as the expansion of capacity for plastics products and medical systems in North America. In the Primary Packaging Glass Division, capital expenditure mainly related to the construction of a new furnace at the Lohr site (Germany) and capacity expansions for injection vials in Morganton (NC/USA).
Page 5
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Forecast 2025 5 Based on the course of business to date, the company now ex- pects the following development for the 2025 financial year: Key performance indicator Basis Adjusted Forecast 20254) Adjusted Forecast 2025 Revenues EUR 2,400.0m1) Organic growth between 0% and 2% Organic decline between -4% to -2% Adjusted EBITDA margin - Around 20% (currency-adjusted) Around 18.5% to 19% (organic) Adjusted EPS in euros EUR 4.852) Decline in the low-double-digit percentage range (currency-adjusted)3) Decline in the mid-double-digit percentage range (currency-adjusted) 1) Based on the revenues for the financial year 2024, including revenues of Bormioli Pharma, translated at the budgeted exchange rates for the financial year 2025. 2) Based on adjusted EPS for the financial year 2024, excluding the earnings contributions of Bormioli Pharma, translated at the budgeted exchange rates for the financial year 2025, based on 34.540m shares. 3) High single-digit percentage range is the range between 7 and 9%. 4) Adjusted forecast as of July 10, 2025. Duesseldorf (Germany), October 10, 2025 The Management Board Forecast 2025
Page 6
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Financial Information 6 Net financial debt In EUR m Aug. 31, 2025 Nov. 30, 2024 Change Promissory loans – November 2015 (nominal) 25.5 25.5 – Promissory loans – September 2017 (nominal) 45.5 45.5 – Promissory loans – November 2020 (nominal) 162.0 162.0 – Promissory loans – November 2021 (nominal) 75.0 75.0 – Promissory loans – November 2022 (nominal) 300.0 300.0 – Promissory loans – October 2024 (nominal) 600.0 600.0 – Revolving credit facilities 102.0 – 102.0 Bridge loan acquisition Bormioli Pharma 725.0 – 725.0 Local credit facilities and overdraft facilities 36.1 8.7 27.4 Liabilities from lease, factoring and installment purchases 90.7 70.0 20.7 Financial debt 2,161.8 1,286.7 875.1 Cash and cash equivalents 145.9 186.4 –40.5 Net financial debt 2,015.9 1,100.3 915.6 At the end of August 2025, Gerresheimer took out two loans to- taling EUR 200m for the early repayment of part of the bridge loan for the acquisition of Bormioli Pharma. The loan s have a term until 2027 and 2028, respectively, and bear variable interest rates. The disbursements were made at the beginning of September 2025. The change in net financial debt is mainly due to the utilization of bridge loan for the acquisition of Bormioli Pharma. This bridge loan has a term until September 2027. Adjusted EBITDA leverage, i.e. the ratio of net financial debt to adjusted EBITDA for the last twelve months, was 4.15x as of the reporting date (November 30, 2024: 2.43x) . Gerresheimer is therefore complying with its covenants. Capital structure In % of total assets Aug. 31, 2025 Nov. 30, 2024 Non-current assets 76.8 73.9 Current assets 23.2 26.1 Equity 30.5 40.4 Financial debt 46.1 33.8 Other non-current liabilities 9.5 9.7 Other current liabilities 13.9 16.1 Financial Information for the third quarter and the first nine months of the financial year 2025
Page 7
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Financial Information 7 Consolidated Income Statement for the first nine months of the financial year 2025 In EUR k Q3 2025 Q3 2024 9M 2025 9M 2024 Revenues 560,682 498,514 1,681,391 1,467,030 Cost of sales –421,789 –350,677 –1,257,918 –1,040,945 Gross profit on sales 138,893 147,837 423,473 426,085 Selling and general administrative expenses –100,982 –95,081 –309,456 –281,581 Research and development expenses –5,565 –4,766 –14,840 –15,485 Other operating income 6,400 8,065 42,044 26,994 Other operating expenses –31,364 –7,672 –68,051 –20,107 Operating income 7,382 48,383 73,170 135,906 Interest income 627 809 2,845 2,820 Interest expenses –23,359 –15,458 –89,468 –43,160 Other financial result 337 1,419 1,900 3,666 Financial result –22,395 –13,231 –84,723 –36,674 Income before income taxes –15,013 35,152 – –11,553 99,232 Income taxes 2,742 –7,485 –584 –25,208 Net income –12,271 27,667 –12,137 74,024 Shareholders of Gerresheimer AG –12,701 27,209 –13,691 72,679 Non-controlling interests 430 458 1,554 1,345 Basic and diluted earnings per share in euros –0.37 0.79 –0.40 2.10
Page 8
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Financial Information 8 Consolidated Balance Sheet as of August 31, 2025 In EUR k Aug. 31, 2025 30.11.2024 Assets Intangible assets 1,711,129 1,241,173 Property, plant and equipment 1,815,121 1,506,265 Investment property 1,752 1,752 Investments accounted for using the equity method 19,469 20,513 Income tax receivables 1,596 4,038 Other financial assets 19,024 21,894 Other non-financial assets 3,617 3,844 Deferred tax assets 26,088 17,384 Non-current assets 3,597,796 2,816,863 Inventories 511,378 355,088 Trade receivables 267,672 310,641 Contract assets 23,465 13,191 Income tax receivables 13,177 8,388 Other financial assets 27,297 31,571 Other non-financial assets 100,115 83,903 Cash and cash equivalents 145,871 186,378 Non-current assets held for sale and discontinued operations – 3,141 Current assets 1,088,975 992,301 Total assets 4,686,771 3,809,164 Equity and liabilities Subscribed capital 34,540 34,540 Capital reserve 778,475 778,475 Accumulated other comprehensive income –145,389 –47,665 Retained earnings 734,246 746,212 Shareholders of Gerresheimer AG 1,401,872 1,511,562 Non-controlling interests 25,926 27,579 Equity 1,427,798 1,539,141 Provisions for pensions and similar obligations 95,539 98,758 Other provisions 12,397 12,736 Financial debt 1,705,667 916,651 Contract liabilities 75,767 73,048 Other financial liabilities 11,194 15,102 Other non-financial liabilities 56,854 51,882 Deferred tax liabilities 193,815 116,343 Non-current liabilities 2,151,233 1,284,520 Provisions for pensions and similar obligations 12,515 12,589 Other provisions 47,002 26,575 Financial debt 456,100 370,031 Trade payables and other liabilities 297,613 354,582 Contract liabilities 9,582 5,165 Income tax liabilities 17,418 16,227 Other financial liabilities 148,802 92,063 Other non-financial liabilities 118,708 108,271 Current liabilities 1,107,740 985,503 Total equity and liabilities 4,686,771 3,809,164
Page 9
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Financial Information 9 Consolidated Statement of Cash Flows for the period from December 1, 2024, to August 31, 2025 In EUR k 9M 2025 9M 2024 Net income –12,137 74,024 Income taxes 584 25,208 Financial result 84,723 36,674 Amortization/depreciation/impairment losses 200,936 146,517 Result of associated companies and other investment income 1,044 1,000 Change in provisions 6,380 –6,838 Result of disposals of non-current assets/liabilities 74 –712 Interest paid –51,499 –30,457 Interest received 2,029 1,717 Income taxes paid –30,206 –43,802 Income taxes received 3,073 13,048 Change in inventories –67,331 –46,955 Change in trade receivables as well as contract assets 49,027 5,680 Change in trade payables and other liabilities as well as contract liabilities –38,856 –36,280 Change in net working capital –57,160 –77,555 Other non-cash-effective items –28,050 –32,317 Cash flow from operating activities 119,791 106,506 Cash received from disposals of non-current assets 2,545 2,159 Cash paid for capital expenditure in intangible assets and property, plant and equipment –250,413 –279,927 Payments received from government grants 9,280 18,424 Cash paid for capital expenditure in fully consolidated companies as well as other equity investments –361,587 –9,331 Cash received in connection with divestments 5,821 – Cash flow from investing activities –594,354 –268,675 Dividend payments to third parties –2,357 –45,431 Repayment of bonds (acquisition Bormioli Pharma) –350,000 – Raising of revolving credit facilities 177,000 329,963 Raising of credit facilities - bridge loan acquisition Bormioli Pharma 780,000 – Repayment of revolving credit facilities –75,000 –122,260 Repayment of credit facilities - bridge loan acquisition Bormioli Pharma –55,000 – Raising of other liabilities to banks 44,518 6,257 Repayment of other liabilities to banks –63,270 –9,145 Cash paid for leases and installment purchase liabilities –20,284 –16,181 Other issues from financing activities 2,519 106 Cash flow from financing activities 438,126 143,309 Changes in financial resources –36,437 –18,860 Effect of exchange rate changes on financial resources –12,902 –3,503 Financial resources at the beginning of the period 183,941 122,264 Financial resources at the end of the period 134,602 99,901 Components of the financial resources Cash and cash equivalents 145,871 109,450 Overdraft facilities –11,269 –9,549 Financial resources at the end of the period 134,602 99,901 A consideration of EUR 389.6m was paid for the acquisition of Bormioli Pharma, as well as EUR 0.9m for the repayment of a shareholder loan. Cash and cash equivalents amounted to EUR 28.0m at the time of acquisition. The purchase price allocation had not yet been completed at the time of preparing the quarterly statement.
Page 10
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 Financial Information 10 Reconciliation of Adjusted EBITDA to Net Income for the first nine months of the financial year 2025 In EUR m 9M 2025 9M 2024 Change Adjusted EBITDA Plastics & Devices 222.6 208.5 14.1 Adjusted EBITDA Primary Packaging Glass 127.2 119.7 7.5 Adjusted EBITDA Advanced Technologies –12.3 –13.6 1.3 Adjusted EBITDA Corporate functions/consolidation –23.6 –21.9 –1.7 Adjusted EBITDA 313.9 292.7 21.2 Depreciation/amortization and impairment losses –150.8 –114.4 –36.4 Depreciation/amortization and impairment losses of fair value adjustments –49.6 –28.6 –21.0 Exceptional income and expenses including restructuring –40.3 –13.8 –26.5 Operating income 73.2 135.9 –62.7 Financial result –84.7 –36.7 –48.0 Income taxes –0.6 –25.2 24.6 Net income –12.1 74.0 –86.1 Depreciation/amortization and impairment losses of fair value adjustments 49.6 28.6 21.0 Exceptional income and expenses including restructuring 40.3 13.8 26.5 Exceptional expenses on financial result 22.9 – 22.9 Tax effects –28.4 –9.3 –19.1 Adjusted net income 72.3 107.1 –34.8 Non-controlling interests 1.6 1.4 0.2 Adjusted net income attributable to shareholders of Gerresheimer AG 70.8 105.7 –34.9 Adjusted EPS attributable to shareholders of Gerresheimer AG in euros 2.05 3.06 –1.01 Amortization and impairment losses of fair value adjustments related in the first nine months of the financial year 2025 to the subsequent measurement of intangible assets identified in con- nection with the acquistions made in the period 2007 to 2018. At the beginning of the financial year 2025, Gerresheimer ex- panded the scope of depreciation, amortization and impairment losses of fair value adjustments to include depreciation, amor- tization and impairment losses related to the subsequent meas- urement of property, plant and equipment, in particular to properly reflect the significant effects of the purchase price al- location in connection with the acquisition of Bormioli Pharma. As a result, depreciation, amortization and impairment losses of fair value adjustments in the first nine months of the financial year 2025 derive from subsequent measurement of intangible assets and property, plant and equipment. The new definition applies for the first time to subsequent measurement in con- nection with the acquisition of Bormioli Pharma. Depreciation, amortization and impairment lo sses from subsequent measurement of property, plant and equipment from acquis- tions made in the period 2007 to 2018 are not adjusted. In the first nine months of the financial year 2025, fair value ad- justments were exclusively subject to scheduled depreciation and amortization. Net income in the first nine months of 2025 was negatively im- pacted by exceptional income and expenses including restruc- turing totaling EUR 40.3m (prior-year period: EUR 13.8m), which are mainly attributable to the following special effects: In EUR m 9M 2025 9M 2024 Change Restructuring 16,660 1,227 15,433 Construction of new plants 11,248 4,674 6,574 Acquisition/divestment 6,864 871 5,993 Reorganization of divisions 3,262 1,711 1,551 Environmental issues 861 1,511 –650 Inflation compensation premium – 2,991 –2,991 Other income and expenses 1,451 812 639 Exceptional income and expenses including restructuring 40,346 13,797 26,549 Restructuring expenses relate to initial measures in connection with structural and cost efficiency programmes in all business areas. Additional measures are planned for the remainder of the current financial year. The one-off items in connection with acquisitions and divest- ment mainly comprise the expenses from the acquisition of Bor- mioli Pharma and the income from the sale of the remaining shares in Securetec Detektions -Systems AG, Neubiberg (Ger- many). Expenses for new plant construction mainly comprise expenses in connection with the expansion of our plants in Skopje (Republic of North Macedonia ), Peachtree (GA/USA) and Queretaro (Mexico). The expenses for reorganization in the divisions mainly relate to measures in the Primary Packaging Glass division. The one-off items from environmental issues largely comprise the expenses and insurance payments received in connection with the damage caused by Hurricane Helene at the Morganton site in the USA.
Page 11
Gerresheimer AG QUARTERLY STATEMENT Q3 2025 11 Financial Calendar February 26, 2026 Publication Annual Report 2025 April 16, 2026 Publication Quarterly Statement for the 1st Quarter 2026 June 3, 2026 Annual General Meeting 2026 July 14, 2026 Publication Half-year Financial Report 2026 Share Reference Data ISIN DE000A0LD6E6 German Securities Identification Number (WKN) A0LD6E Bloomberg ticker symbol GXI Reuters ticker symbol GXIG.DE Imprint Publisher Gerresheimer AG Peter-Müller-Strasse 3 40468 Duesseldorf Germany Phone +49 211 6181-00 Fax +49 211 6181-295 E-Mail info@gerresheimer.com www.gerresheimer.com Disclaimer This Quarterly Statement contains certain future-oriented statements. Future-oriented statements include all statements that do not relate to historical facts and events and contain future-oriented expressions such as “believe”, “estimate”, “assume”, “expect”, “forecast”, “intend”, “could” or “should” or expressions of a similar kind. Such future -oriented statements are subject to risks and uncertainties since they relate to future events and are based on the Company’s current assumptions, which may not in the future take place or be fulfilled as expected. The Company points out that such future -oriented statements provide no guarantee for the future and that actual events, including the financial position and profitability of the Gerresheimer Group and developments in the economic and regulatory fundamentals, may vary substantially (particularly on the down side) from tho se explicitly or implicitly assumed or described in these statements. Even if the actual results for the Gerresheimer Group, including its financial position and profita- bility and the economic and regulatory environment, are in accordance with such future-oriented statements in this Quar- terly Statement, no guarantee can be given that this will con- tinue to be the case in the future. Note regarding the rounding of figures Due to the commercial rounding of figures and percentages, small deviations may occur. Remarks on calculation All changes in percent were calculated on a thousand-euro basis. Slight deviations may therefore occur when stating fig- ures in millions of euros in the tables. Note regarding the translation This Quarterly Statement is the English translation of the origi- nal German version; in case of deviations between these two, the German version prevails. Additional Information